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Abstract 
Purpose: To demonstrate the safety and feasibility of leveraging therapeutic antibodies for surgical 
imaging.  
Procedures: We conducted two phase I trials for anti-epidermal growth factor receptor 
antibodies cetuximab-IRDye800CW (n=12) and panitumumab-IRDye800CW (n=15). Adults with 
biopsy-confirmed head and neck squamous cell carcinoma scheduled for standard-of-care surgery 
were eligible. For cetuximab-IRDye800CW, cohort 1 was intravenously infused with 2.5 mg/m2, 
cohort 2 received 25 mg/m2, and cohort 3 received 62.5 mg/m2. For panitumumab-IRDye800CW, 
cohorts received 0.06 mg/kg, 0.5 mg/kg, and 1 mg/kg, respectively. Electrocardiograms and blood 
samples were obtained, and patients were followed for 30 days post-study drug infusion.  
Results: Both fluorescently labeled antibodies had similar pharmacodynamic properties and 
minimal toxicities. Two infusion reactions occurred with cetuximab and none with panitumumab. 
There were no grade 2 or higher toxicities attributable to cetuximab-IRDye800CW or 
panitumumab-IRDye800CW; fifteen grade 1 adverse events occurred with cetuximab-I 
RDye800CW, and one grade 1 occurred with panitumumab-IRDye800CW. There were no 
significant differences in QTc prolongation between the two trials (p=0.8). 
Conclusions: Panitumumab-IRDye800CW and cetuximab-IRDye800CW have toxicity and 
pharmacodynamic profiles that match the parent compound, suggesting that other therapeutic 
antibodies may be repurposed as imaging agents with limited preclinical toxicology data. 
 
Introduction 
Although medical technology has significantly 
advanced over decades, surgeons still primarily rely 
on imprecise methods of direct visualization and 
non-specific tactile feedback to determine surgical 
margins. There are many clinical trials using 
fluorescent contrast agents to minimize morbidity 
associated with resection of normal tissue that may 
also advance oncological outcomes by improving the 
completeness of tumor resections in gliomas, breast 











Figure 1. Flow diagram of the cetuximab-IRDye800CW and panitumumab-IRDye800CW clinical trials. 
 
Cetuximab is a human/mouse recombinant 
monoclonal IgG1 antibody that specifically binds to 
the extracellular domain of the epidermal growth 
factor receptor (EGFR). Cetuximab was approved by 
the United States Food and Drug Administration 
(FDA) in February 2004 for treatment of metastatic 
colorectal cancer and approved in March 2006 for 
treating locally or regionally advanced head and neck 
squamous cell carcinoma (HNSCC.) We have 
previously conjugated cetuximab to the near-infrared 
fluorescence dye IRDye800CW for molecular 
fluorescence-guided imaging for surgical navigation 
in head and neck resections [6,7]. While the 
cetuximab-IRDye800CW study showed promising 
results, we strove to improve our tumor-to- 
background ratio (TBR) for better intraoperative 
imaging contrast and to optimize the safety and 
dosing requirements of our targeting antibody.  
Panitumumab is a fully-humanized monoclonal 
IgG2 antibody with a different binding epitope from 
cetuximab. Panitumumab has about an eight-times 
stronger and more specific binding to EGFR [8,9]. 
Panitumumab was first approved by the FDA in 
September 2006 for EGFR-expressing metastatic 
colorectal cancer. Although panitumumab has 
improved EGFR binding, previous preclinical data in 
mice have shown that panitumumab-IRDye800CW 
has similar TBRs compared with cetuximab- 
IRDye800CW both in vitro and in vivo [10]. However, 
since panitumumab is a fully-humanized antibody 
and cetuximab is a chimeric human-mouse antibody, 
panitumumab may have a safety advantage over 
cetuximab, as it has been shown to have fewer severe 
infusion reactions and potentially fewer other adverse 
effects [11-13]. Whether this improved safety for the 
antibody holds true for the antibody-dye complex as 
well is unknown. On a broader level, the safety of 
using therapeutic antibodies for tumor-specific 
imaging has not been well-characterized.  
Therefore, in this study, we demonstrate our 
experience with the overall safety profile of 
fluorescently labeled antibodies, presenting data from 
our first-in-human trials with panitumumab- 
IRDye800CW and cetuximab-IRDye800CW.  
Methods 
Study design 
We conducted two, open-label phase I trials to 
determine the safety profile of panitumumab- 
IRDye800CW and cetuximab-IRDye800CW. The 
cetuximab-IRDye800CW study was approved by the 
University of Alabama at Birmingham (UAB) 
Institutional Review Board (IRB), the Stanford 
University IRB, and the FDA (NCT01987375). The 
panitumumab-IRDye800CW study was approved by 
the Stanford University IRB and the FDA 
(NCT02415881). Sample size was calculated based on 
the conventional 3+3 phase I dose escalation model.  
Adults with primary or recurrent 
biopsy-confirmed HNSCC scheduled to undergo 
standard-of-care surgery with curative intent were 
eligible for the study. Patients were required to have a 
life expectancy of more than 12 weeks with a 
Karnofsky performance status of at least 70% or 
ECOG/Zubrod level 1. Patients with QT prolongation 
on baseline electrocardiogram (ECG) (greater than 
440 ms in males, and 450 ms in females), abnormal 
magnesium or potassium levels, previous infusion 
reactions to monoclonal antibodies, or significant liver 
or cardiovascular disease were excluded. Patients 
receiving Class IA or Class III antiarrhythmic agents 
were also ineligible. Written informed consent was 
obtained from all patients.  
A schematic overview of the trials is given in 
Figure 1. One to five days prior to surgery, patients 
were intravenously infused with a 10 or 100 mg dose 
of unlabeled cetuximab or 100 mg panitumumab as a 





loading dose. In the panitumumab-IRDye800CW 
study, an ECG was obtained at this time. If the patient 
did not have a drug (infusion) reaction, the 
conjugated antibody-dye complex (cetuximab- 
IRDye800CW or panitumumab-IRDye800CW) was 
infused. For cetuximab-IRDye800CW, cohort 1 
received a microdose of 2.5 mg/m2 (1/100 of one 
therapeutic dose), cohort 2 received 25 mg/m2 (1/10), 
and cohort 3 received 62.5 mg/m2 (1/4). For 
panitumumab-IRDye800CW, cohort 1 received a 
microdose of 0.06 mg/kg (1/100 of one therapeutic 
dose), cohort 2 received 0.5 mg/kg (1/12), and cohort 
3 received 1 mg/kg (1/6). In the cetuximab- 
IRDye800CW study, a repeat ECG was obtained 30 
min after infusion of the antibody-dye complex. Both 
trials obtained an ECG 2 h (± 1 h) following infusion 
of the dye-conjugated study drug. Standard-of-care 
surgery was performed 1-5 days after antibody-dye 




Cetuximab (Erbitux; Bristol-Myers Squibb, New 
York City, New York, United States) is a chimeric 
monoclonal antibody composed of the Fv regions of 
mouse anti-EGFR antibodies with human immuno-
globulin G1 (IgG1) heavy and kappa light chain (152 
kDa). Cetuximab was concentrated and pH adjusted 
to pH 8.5 in a 10 mg/mL solution in 50 mM potassium 
phosphate buffer using Amicon Ultra-15 devices 
(50,000 MWCO, EMD Millipore, Millerica MA) at the 
UAB Vector Production Facility under good 
laboratory practice (GLP) conditions, as previously 
described [14]. Cetuximab was then conjugated to 
IRDye800CW (IRDye800CW-N-hydroxysuccinimide 
ester, LI-COR Biosciences, Lincoln, Nebraska, United 
States) for 2 h at 20 ºC in the dark at a molar ratio of 
2.3:1. The cetuximab-IRDye800CW conjugate was 
layered onto spin columns and centrifuged to 
separate conjugate from free dye and concentrated to 
2 mg protein per mL. Quality control testing was 
performed by SDS-PAGE analysis, HPLC analysis, 
pH, EGFR binding, and sterility. The dye-to-protein 
ratio was confirmed to be 2.3:1 [14]. 
Panitumumab (Vectibix; Amgen, Thousand 
Oaks, California, United States) is a fully humanized 
recombinant monoclonal antibody with human 
immunoglobulin G2 (IgG2) heavy and kappa light 
chain (147 kDa). Panitumumab-IRDye800CW was 
manufactured under similar conditions to cetuximab- 
IRDye800CW and was produced at the same 2.3:1 
dye-to-protein ratio [14,15]. Panitumumab solution 
was incubated with IRDye800CW at a 2.3:1 
dye-to-protein ratio in the dark for 2 h at 20 °C. The 
mixture was purified, and the unconjugated dye was 
removed by desalting columns (Pierce Biotechnology, 
Rockford, Illinois, United States) and concentrated, as 
previously described [15]. Quality control was 
performed to measure the protein concentration, 
sterility, pH, HPLC analysis, and dye-to-antibody 
ratio. 
Adverse events 
Adverse events were categorized according to 
the National Cancer Institute Common Terminology 
Criteria (Version 4.0). Safety data and adverse events 
were collected at 15 days, and patients were followed 
for 30 days post-infusion. General physical exam and 
Karnofsky performance status were assessed prior to 
enrollment and on the day of surgery, day 15, and day 
30. Serum chemistry, metabolic panels, complete 
blood count, prothrombin/partial thromboplastin 
times, and thyroid stimulating hormone levels were 
obtained on day 0, the day of surgery, and as needed 
up to 30 days post-infusion of the study drug. ECGs 
were performed at screening, 30 min post-infusion of 
the unlabeled-antibody loading dose, 2 h (±1 h) 
post-infusion of the antibody-dye complex, and at 
follow-up on day 30. 
Pharmacokinetics 
 Patient blood samples were obtained prior to 
study drug infusion, 30 min to 1 h post-infusion, at the 
day of surgery, and at 2-4 weeks follow-up. The blood 
samples were spun down to collect the plasma, and 
the antibody-dye complex concentrations in plasma at 
the different time points were assayed.  
The assessment of plasma concentration for the 
cetuximab-IRDye800CW trial has been previously 
described [6]. Briefly, aliquots of plasma sample were 
resolved by NuPAGE 4-12% Bis-Tris gel (Invitrogen 
Corporation; Carlsbad, CA), assessed by gel 
electrophoresis (35 min at 150 V), imaged at 800 nm 
(Pearl Impulse, LI-COR Biosciences; Lincoln, 
Nebraska, United States), and quantified by 
calculating regions-of-interest (ROIs) (Image Studio, 
LI-COR Biosciences).  
For the panitumumab-IRDye800CW trial, the 
same process was used to verify panitumumab- 
IRDye800CW at the 150 kDa protein marker. The 
antibody-dye complex in the patient plasma was 
assayed with the Spark multimode microplate reader 
(Tecan Group Ltd., Männedorf, Zürich, Switzerland) 
with an excitation of 775 nm and emission of 805 nm 
at room temperature. Aliquots of plasma sample (3 
µL) were diluted in UltraPure distilled water 
(Invitrogen, Thermo Fisher Scientific, Carlsbad, 
California, United States) (45 µL) and measured in 
Greiner Bio-One FLUOTRAC black, 96-well half-area 





clear-bottom microplates (Thermo Fisher Scientific) 
against a set of panitumumab-IRDye800CW stand-
ards. Fluorescence measurements were done in 
triplicate in separate microplates, and the plasma 
concentration was determined through comparison 
with the standards. Total plasma values (mg) of both 
antibody-dye complexes at each time point were 
calculated based on patient dose and estimated total 
body plasma (calculated based on patient weight). 
Statistical analysis 
 Descriptive statistics and figures were 
performed using Microsoft Office 2017 (Version 15.41, 
Microsoft, Redmond, Washington, United States), 
GraphPad Prism (Version 6.0c, GraphPad Software, 
La Jolla, California, United States), and R (Version 
3.0.1) for unpaired t-tests and Fisher’s exact test. 
Outliers were not excluded from the study data 




Fourteen patients were enrolled in the 
cetuximab-IRDye800CW trial, of which two were 
excluded because of infusion reactions (see Adverse 
Events section). Fifteen patients were enrolled in the 
panitumumab-IRDye800CW trial. The average age 
was 59.5±14.1 years and 66.0±14.0 years, respectively. 
There were no statistically significant differences in 
age (p=0.2), sex (p=0.4), anatomic origin of the cancer 
(p=0.9), primary tumor site (p=0.9), cancer stage 
(p=0.5), history of chemotherapy (p=1), history of 
radiation therapy (p=0.6), or the surgical procedure 
performed (p=0.3) between the cetuximab-IRDye 
800CW and the panitumumab-IRDye800CW patient 
populations (Table 1). 
Adverse events 
 Two patients had infusion reactions following 
the infusion of unlabeled cetuximab in the 
cetuximab-IRDye800CW trial. These two patients did 
not proceed with the infusion of the antibody-dye 
complex and the rest of the trial and were excluded 
from further analysis. These reactions included 
flushing, hypotension and tachycardia that resolved 
with cessation of cetuximab. In the remaining twelve 
patients that did receive cetuximab-IRDye800CW, 
there were no infusion reactions specifically to the 
antibody-dye complex. There were no infusion 
reactions to panitumumab or panitumumab-IRDye 
800CW (n=15).  
A total of 15 adverse events occurred in the 
cetuximab-IRDye800CW trial, and one adverse event 
was observed in the panitumumab-IRDye800CW 
trial. All of these events were grade 1 (Table 2). There 
was a significant difference (p=0.01) in the average 
number of adverse events per patient with 
cetuximab-IRDye800CW (1.06±0.35) compared to 
panitumumab-IRDye800CW (0.11±0.19). The most 
common adverse events were: tumor site irritation (3 
patients), ECG changes (3 patients), elevated AST (2 
patients), and hypomanesemia (2 patients).  
 
Table 1. Comparison of demographics and characteristics of 









(years ± SD) 
59.5 ± 14.1 66.0 ± 14.0 0.2 
Sex    
Male 8 (66.7%) 13 (86.7%) 0.4 
Female 4 (33.3%) 2 (13.3%)  
Cancer Origin    
Oral Cavity 8 (66.7%) 11 (73.3%) 0.9 
Cutaneous 2 (16.7%) 1 (6.7%)  
Nasal Cavity 1 (8.3%) 2 (13.3%)  
Pharynx 1 (8.3%) 1 (6.7%)  
Tumor Site    
Oral Cavity 7 (58.3%) 11 (73.3%) 0.9 
Oropharynx 1 (8.3%) 1 (6.7%)  




1 (8.3%) 2 (13.3%)  
Neck 1 (8.3%) 0  
Cutaneous 2 (16.7%) 1 (6.7%)  
Cancer Stage    
Stage I 0 1 (6.7%) 0.5 
Stage II 2 (16.7%) 4 (26.7%)  
Stage III 5 (42.7%) 2 (13.3%)  
Stage IVA 4 (33.3%) 7 (46.7%)  
Stage IVB 1 (8.3%) 1 (6.7%)  
Prior 
Chemotherapy 
1 (6.7%) 2 (13.3%) 1 









Glossectomy 3 (25.0%) 4 (26.7%) 0.9 
Wide Local 
Excision  








Other* 2 (16.7%) 3 (20.0%)  
 *Maxillectomy (1), marginal mandibulectomy (1), neck dissection (1), rhinectomy 
(1), tonsillectomy (1). 
 
QTc intervals 
Preclinical toxicology studies on cetuximab- 
IRDye800CW in non-human primates had demonst-
rated a small, but tatistically significant increase in QT 
interval [14]. Consistent with FDA guidance on 
evaluation of the QT interval for agents under clinical 
investigation (E14 Clinical Evaluation of QT/QTc 
Interval Prolongation and Proarrhythmic Potential for 
Non-Antiarrhythmic Drugs), we evaluated pre- and 
post-infusion ECGs. ECGs were obtained at screening, 
after the infusion of the antibody-dye complex, and at 





30-day follow-up in both trials. The panitu-
mumab-IRDye800CW trial obtained an additional 
ECG after the infusion of the unlabeled panitumumab 
(Figure 1). The cetuximab-IRDye800CW trial perfor-
med two ECGs after infusion of the antibody-dye 
complex (Figure 1), and the QTc intervals from both 
were averaged to obtain a single post-infusion value.  
In both trials, the QTc change was, on average, 
less than 5% of the baseline interval length (Figure 2; 
Table 3). There was no significant difference in the 
average QTc interval change between cetuximab- 
IRDye800CW and panitumumab-IRDye800CW imm-
ediately after infusion of the antibody-dye complex 
(1.1% vs. 1.3%, p=0.9) or at 30-day follow-up (0.5% vs. 
2.9%, p=0.3) (Table 3). 
Given that some of the QTc intervals dropped 
below the baseline value, we additionally analyzed 
the absolute percentage of the QTc interval change. 
There was no significant difference in the average 
absolute value QTc interval change between the two 
study drugs either immediately after the infusion of 
the antibody-dye complex (3.3% vs. 3.6%, p=0.8) or at 
30 days post-infusion (4.2% vs. 3.4%, p=0.6) (Table 3). 
Three of the ten (30%) patients with normal 
baseline QTc intervals in the cetuximab-IRDye800CW 
trial had an abnormal QTc interval (defined as 
greater than 440 ms in males, and 450 ms in 
females) at some point after study drug infusion 
through day 30. Two patients in the 
cetuximab-IRDye800CW trial had abnormal QTc 
intervals at baseline but were included in the trial 
because their QT intervals were within inclusion 
range. In the panitumumab-IRDye800CW trial, two of 
the fifteen (13.3%) total patients with normal baseline 
QTc intervals were observed to have an abnormal 
QTc at some point after infusion of the unlabeled 
panitumumab through day 30. There was no 
significant difference between the two (p=0.4). 
In the panitumumab-IRDye800CW trial, one 
patient had a 19% increase in the QTc interval at 
30-day follow-up. This change was determined to be 
most likely due to concurrent administration of 
highly-active antiretroviral therapy (HAART) and 
antibiotics, and less likely to be due to the study drug.  
Pharmacokinetics 
 Patients in the cetuximab-IRDye800CW trial 
received on average 5.2±0.7 mg (2.5 mg/m2) in cohort 
1, 48.8±5.2 mg (25 mg/m2) in cohort 2, and 130.4±26.9 
(62.5 mg mg/m2) cetuximab-IRDye800CW in cohort 3 
(Table 4). Patients in the panitumumab-IRDye800CW 
trial received on average 4.7±0.7 mg (0.06 mg/kg) in 
cohort 1, 39.2±6.9 mg (0.5 mg/kg) in cohort 2, and 
69.1±12.3 mg (1 mg/kg) panitumumab-IRDye800CW 
in cohort 3 (Table 4). 
Table 2. Comparison of adverse events that occurred in the 









Cohort 1  n=3 n=3  
     Grade 1 4 1  
          Elevated AST 1/4 (25.0%) 0  
          Tumor Site Irritation 2/4 (50.0%) 0 
          ECG Changes 0 1/1 (100.0%) 
          Sinus Bradycardia 1/4 (25.0%) 0 
     Grade 2 - 5 0 0 
 Cohort 2 n= 6 n=5  
     Grade 1 7 0 
          Elevated AST 1/7 (14.3%)  
          Tumor Site Irritation 1/7 (14.3%)  
          ECG Changes 2/7 (28.6%)  
          Hypomagnesemia 2/7 (28.6%)  
          Dizziness 1/7 (14.3%)  
     Grade 2 - 5 0 0 
Cohort 3  n=3 n=7  
     Grade 1 2 0 
          Tumor Site Irritation 1/2 (50.0%)  
          Hypotension 1/2 (50.0%)  
     Grade 2 - 5 0 0 
Total Adverse Events 15 1  
Average Events/Patient ± SD 1.06 ± 0.35 0.11 ± 0.19 0.01* 
*Statistically significant at p<0.05. 
Table 3. Analysis of the average and average absolute value QTc 
interval changes at different study time points in in the 








Post-Loading Dose    
Average QTc Change (%)      n.d. 2.2 ± 4.5  
Average Absolute QTc Change (%)  4.1 ± 2.8  








Average QTc Change (%)      1.1 ± 4.5 1.3 ± 5.0 0.9 
Average Absolute QTc Change (%) 3.3 ± 2.3 3.6 ± 3.5 0.8 
30 Days Post-Infusion    
Average QTc Change (%)      0.5 ± 5.7 2.9 ± 5.2 0.3 
Average Absolute QTc Change (%) 4.2 ± 3. 3.4 ± 4.8 0.6 
n.d.: not determined.  
 
Plasma concentration of panitumumab-IRDye 
800CW and cetuximab-IRDye800CW were measured 
at different time points after infusion of the 
antibody-dye complex (Table 4; Figure 3). For all 
three doses, the calculated half-life for 
cetuximab-IRDye800CW was 25 h in cohort 1, 24 h in 
cohort 2, and 32 h in cohort 3, similar to as previously 
demonstrated [15]. For all doses of panitumumab- 
IRDye800CW evaluated, the calculated half-life was 
33 h in cohort 2, and 23 h in cohort 3. In the 
panitumumab-IRDye800CW cohort 1, plasma 
concentrations were too low to calculate the half-life 
accurately. Fluorescent gel electrophoresis of 
panitumumab-IRDye800CW confirmed that the 
antibody-dye complex mostly remained intact in 
patient plasma (Figure S1). 





Table 4. Dosing by cohort for the cetuximab-IRDye800CW and the panitumumab-IRDye800CW trials.  
  Cohort 1 Cohort 2 Cohort 3 
 Cetux800 Pan800 Cetux800 Pan800 Cetux800 Pan800 
Dosage  2.5  0.06  25  0.5  62.5  1  












Average Dose Received 
(mg ± SD) 
5.2 ± 0.7 
 
4.7 ± 0.7 
 
48.8 ± 5.2 
 
39.2 ± 6.9 
 
130.4 ± 26.9 69.1 ± 12.3 












3 hours post-infusion 5.4 ± 0.7  
 
0.7 ± 0.1 50.0 ± 3.5 
 
43.1 ± 3.1 94.7 ± 23.0 69.0 ± 5.8 










Figure 3. Total calculated plasma volume (mg) over time in all cohorts in both 
the cetuximab-IRDye800CW and the panitumumab-IRDye800CW trials. 
 
Discussion 
We conducted two phase I clinical trials, one 
with panitumumab-IRDye800CW and one previously 
described with cetuximab-IRDye800CW with patients 
undergoing standard-of-care HNSCC resections. The 
patient populations were comparable in terms of 
demographics and had a heterogeneous mixture of 
cancer origins and tumor sites. In terms of safety, both 
of the study fluorescently labeled antibodies were 
shown to be safe with only a few grade 1 adverse 
events observed that could be related or possibly 
related specifically to the dye-drug conjugate beyond 
the antibody alone. Because only one dose is 
administered and the dosages used for intraoperative 
imaging are significantly lower than therapeutic 
doses, this may account for the improved safety 
profile of antibody-dye bioconjugates compared to 
the parent compound when used for therapeutic 
purposes [13]. 
The data presented, combined with similar 
antibody-based imaging studies, suggests that the 
known safety profile of therapeutic antibodies can be 
leveraged to develop safe and effective fluorescent 
imaging agents at doses up to 25% of the therapeutic 
dose [1,4,16,17]. This data implies the development of 
additional imaging agents from therapeutic 
antibodies may require only limited toxicology 
studies prior to entry into the clinic—vastly 
expanding the inventory of available imaging agents 
in a highly cost-effective manner.  
Often referred to as combinational medicine [18], 
known elements can be recombined in a unique way 
to provide new value, in this case linking 





well-established, therapeutic antibodies with 
near-infrared fluorescent dyes for use as optical 
imaging agents. Such a conjugated antibody-dye 
complex can have several advantages, including 
general safety, as the safety of the therapeutic 
antibodies and the fluorescent dyes have individually 
been well-characterized and FDA-approved. 
Additionally, the biologics are already produced for 
therapy, which leads to increased cost-effectiveness 
due to the lower cost burden from the initial 
development and manufacturing. Prior research with 
repurposed therapeutic antibodies has also shown a 
high tumor-to-background ratio (TBR) and highly 
specific tumor cell binding on fluorescence 
microscopy, which may be helpful in real-time 
detection of subclinical disease, potentially leading to 
more complete tumor resections and improved 
oncological outcomes in many different cancer types 
[5-7,15,16,19-21]. 
Prior research with the fluorophore-labeled 
cetuximab antibody has shown the feasibility of 
providing real-time, intraoperative guidance [6]. 
Given the encouraging results with cetuximab, we 
chose another anti-EGFR antibody, panitumumab, to 
improve the safety profile and specific tumor- 
targeting. Unlike cetuximab, which is a human-mouse 
chimeric antibody, panitumumab is a fully 
humanized antibody, which decreases the likelihood 
of developing anti-panitumumab antibodies and 
causing an adverse immune response [8]. To further 
characterize the potential differences in drug safety 
and determine if the fluorophore conjugation created 
any unintended safety risks, we compared the safety 
profile of cetuximab-IRDye800CW and panitumu-
mab-IRDye800CW in humans. 
 In our panitumumab-IRDye800CW trial, only 
one adverse event occurred, and the adverse events 
per patient ratio was significantly lower than that of 
cetuximab-IRDye800CW. These results suggest that 
panitumumab-IRDye800CW has an improved safety 
profile over cetuximab-IRDye800CW, which is 
consistent with previous studies showing fewer 
adverse events attributed to unlabeled panitumumab 
compared to cetuximab [13]. 
In our study, there were two infusion reactions 
to the unlabeled cetuximab, but there were no 
reactions to cetuximab-IRDye800CW, or to panitum-
umab and panitumumab-IRDye800CW. This is 
consistent with the decreased infusion reactions 
observed for panitumumab, likely due to its 
fully-humanized nature [13]. Given the lower overall 
imaging dose, it is not surprising that no dermatologic 
adverse events occurred with either study drug. 
Hypomagnesemia, a potential concern with both 
agents due to magnesium wasting secondary to renal 
EGFR inhibition, was not observed in any patients 
[22,23]. The different cohorts largely had the same 
distribution of adverse events with each of the study 
drugs.  
 Another concern for new study drugs is the 
potential for QTc prolongation and arrhythmias. 
Previous data for unlabeled cetuximab showed 
minimal QTc changes [24]. Our study also showed 
minimal QTc interval changes for the antibody-dye 
complex for both cetuximab-IRDye800CW and 
panitumumab-IRDye800CW. The pharmacokinetics 
of panitumumab-IRDye800CW were similar to those 
of cetuximab-IRDye800CW [15]. This half-life of 
approximately one day for both antibody-dye 
complexes is suitable for an infusion time the day 
prior to surgery. Compared to small molecules, the 
longer circulation time of antibody-dye complexes 
may increase background, but it also has the potential 
to improve TBRs, as a fluorescent agent’s sensitivity is 
highly dependent on its cellular uptake and 
accumulation in the target tissue [25]. 
Our study had a limited number of patients 
enrolled in each trial. With this limited number of 
patients, it can be difficult to detect rare adverse 
effects. Other limitations of the study include a 
modified ECG protocol between the two studies, 
which we accounted for by grouping our analysis by 
categories relative to time after the infusion of the 
study drugs. Additionally, the actual number of 
milligrams of study drug delivered were also 
different in both studies due to variations in patient 
weight, as the drugs were dosed by weight- and body 
surface area-based calculations. The reason for these 
different dosages is that the doses given were 
calculated as fractions of the therapeutic dose, which 
is different for both antibodies. The studies were also 
conducted at two separate sites over several years. 
Given our primary interest in patient safety and drug 
toxicity at various doses, the percent of therapeutic 
dose was considered the most important dose 
measure by us. The dose-escalation cohorts for 
panitumumab-IRDye800CW were similar fractions of 
the therapeutic doses (1/100, 1/12, 1/6) compared to 
the fractions for cetuximab-IRDye800CW (1/100, 
1/10, 1/4) to be appropriately comparable between 
the two antibodies.  
The use of these targeting antibodies can provide 
safety advantages over other fluorescence tracers such 
as nanoparticles, affibodies, and nonspecific 
fluorescent dyes with an unknown safety profile. 
Using antibodies that have been FDA-approved and 
have well-established pharmacokinetic and safety 
data may be the most cost-effective method, and 
perhaps the safest approach to surgical imaging. 
However, the general tolerance for adverse effects in 





non-therapeutic drugs is also lower. As optical 
imaging research advances, minimizing patient risk 
and toxicities are necessary to continue moving 
forward.  
Conclusions 
These first-in-human studies suggests that 
antibodies fluorescently labeled with IRDye800CW 
are safe optical agents for fluorescence-guided surgi-
cal navigation. While cetuximab-IRDye800CW and 
panitumumab-IRDye800CW both demonstrated 
excellent safety as imaging agents, panitumumab- 
IRDye800CW shows an improved safety profile. 
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